Solid Biosciences Announces $90 Million Private Placement Solid Biosciences has entered into a securities purchase agreement with a select group of institutional investors and accredited investors for a $90 million private placement, which is expected to close on or about December 15, 2020, subject to the satisfaction of customary closing conditions. The private...
This proved to the market and world governments that their nanotechnology is superior and that it works. Next stop, flu vaccine. I'm holding. Disclaimer: Not financial advice. Just my opinion. See my related posts. Source: www.cnn.com
Great buying opportunity, with a excellent chance to break out of bull flag. A conservative trader would wait for the breakout, but I like the setup now near fib line. Give me your thoughts
I still believe NVAX has a lot of potential and I'll say it again. My idea is clear that its NanoParticle and Matrix-M Adjuvant tech makes it a prime candidate for a COVID-19 vaccines. Even if it doesn't make it first (or ever), it still has major potential for the seasonal influenza (w/ NanoFlu) and its Respiratory Syncytial Virus (RSV) vaccine. Check out my...
Pay close attention to PARADIGM (PAR). 3 Potential Moves 1. We bounce off the .382 Fib level and return to test the 2.80 mark which we saw on 11/05/20 -Being the end of the trading week I suspect the latter. 2. We break the .382 Fib level and Uptrend and head for the 'Golden Pocket' -Bounce off strong support at 2.00 mark -MACD is starting to squeeze but if we...
This IPO was just listed on FEB, 6th 2020 and will be killing it every earnings and has the potential to big a really big play in the market during these times. The chart I have posted is a 4HR time frame. Definitely one to add to your portfolio for awhile! I can see this being a GOLDEN GOOSE to get into early during these times! options plays are good on this one...
If you like this idea, don't forget to hit the Like Button! Alexion business depends on patent-protected therapies in ultrarare and rare diseases of high unmet medical needs. While competitors are entering the market with biosimilars, Alexion still maintains an essential share of the market. My long term view is bullish. However, from a technical point of view,...
I think we will see a sharp move this month. From reading the chart alone I am wagering it's going to be a bullish move... even though the fundamentals of the company are up for debate.
Morningstar weekly highlights set Biomarin Pharmaceuticals with an amazing $119 fair price value ( 50% above current price). Rating: 4 stars Uncertainty rating: Medium Moat: Narrow
This stock popped up on my stock screener the other day. I wanted to document this trade in case it ends up going well. What I'm seeing here on the daily is a break above it's 100 then 200 MA. Now we are in this consolidation period with a little coiling action happening within the triangle I've drawn. It's clear price is going to break in an explosive way...
Watching for ABBV to break this wedge and go higher to fill the gap from earnings.
Warning: High risk pharmaceutical company. I was early in my last chart in January. Chart looks more promising to me now. The company is developing non opioid treatments for joint pain, depression, and Alzheimer's disease. Pipeline (see ling below) is in clinical trials. If trials fail often get large drops in price and vice versa. With the opioid crisis IF these...
BLRX is about to breakout. 6HR Chart Daily: Elliot Waves: Breakout should be imminent...
Weekly chart: we have the downtrend channel clearly defined on a weekly basis. On a monthly basis we have already had a minimum of swing with a dragon fly bullish, on a daily chart some signs of an incoming uptrend as described in the latest posts...but tomorrow...tomorrow is where we play the game with the last resistence in place at 86.72 dollars. Once we get...
See previous for more detail -- just wanted a fresh chart w/ updated targets and a shorter interval.
Biogen's (344.10 at close at the date of this writing) and Eisai's recent success with BAN24O1, an experimental medication for Alzheimer's which is currently in mid-stage clinical trials, in addition to a recent price target raise by Citi, and overall bullish analyst sentiment led to a rally between July 6-9, 2018. Although the clinical trial's success was...